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Abstract
Background: ‘Taste’ changes are commonly reported during chemotherapy. It is unclear to what extent this relates to actual
changes in taste function or to changes in appetite and food liking and how these changes affect dietary intake and
nutritional status.
Patients and methods: This prospective, repeated measures cohort study recruited participants from three oncology clinics.
Women (n= 52) prescribed adjuvant chemotherapy underwent standardised testing of taste perception, appetite and food
liking at six time points to measure change from baseline. Associations between taste and hedonic changes and nutritional
outcomes were examined.
Results: Taste function was significantly reduced early in chemotherapy cycles (p,0.05) but showed recovery by late in the
cycle. Ability to correctly identify salty, sour and umami tastants was reduced. Liking of sweet food decreased early and mid-
cycle (p,0.01) but not late cycle. Liking of savory food was not significantly affected. Appetite decreased early in the cycle
(p,0.001). Reduced taste function was associated with lowest kilojoule intake (r= 0.31; p= 0.008) as was appetite loss with
reduced kilojoule (r= 0.34; p= 0.002) and protein intake (r= 0.36; p= 0.001) early in the third chemotherapy cycle. Decreased
appetite early in the third and final chemotherapy cycles was associated with a decline in BMI (p=,0.0005) over the study
period. Resolution of taste function, food liking and appetite was observed 8 weeks after chemotherapy completion. There
was no association between taste change and dry mouth, oral mucositis or nausea.
Conclusion: The results reveal, for the first time, the cyclical yet transient effects of adjuvant chemotherapy on taste
function and the link between taste and hedonic changes, dietary intake and nutritional outcomes. The results should be
used to inform reliable pre-chemotherapy education.
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Introduction
Taste is one of the five senses and interacts with smell, touch
and other physiological cues to affect the wider perception of
flavor. Taste function is defined as the perception derived when
chemical molecules stimulate taste receptor fields in areas of the
tongue, soft palate and oropharyngeal region of the oral cavity to
perceive the five basic taste qualities (sweet, sour, salty, bitter and
umami) [1], measured via standardised processes [2]. Food
hedonics, which also contributes to flavour perception, encom-
passes food liking: the immediate experience or anticipation of
pleasure from the oro-sensory stimulation of eating a food [3], and
appetite: a psychobiologically based sensation related to the
maintenance of eating and a desire for specific foods [4].
Chemotherapy is known to affect other senses with ototoxicity
and peripheral neuropathy recognized treatment-related toxicities,
which in some cases may be permanent [5,6]. ‘Taste’ changes are
commonly reported by people receiving chemotherapy [7] even
among those who do not report nausea. It is unclear to what extent
this relates to altered taste function per se or to changes to the
sense of smell or touch (including oral dryness) or to hedonic
aspects such as food liking, or appetite, also described colloquially
by patients and clinicians as ‘taste’ [8].
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‘Taste’ changes in oncology populations have been linked to
adverse effects on quality of life, morbidity and mortality due to an
association with inadequate energy and nutrient intake, weight
loss, malnutrition [11], reduced compliance with treatment
regimens [9], reduced immunity [10,11], altered food relationships
[12], changed food rituals [13], emotional distress and interference
with daily life [14]. The extent to which true taste problems play a
role in these scenarios is unknown. The ability to perceive taste
sensations guides food choice, which in itself is a determinant of
health [15]. Because changes in taste function, liking of food and
appetite all have the potential to underpin changes in dietary
intake and nutritional status, understanding the extent of the
contribution of each would help inform the development of
effective interventions in future.
Study Objectives
The primary objective of this study was to measure the effect of
adjuvant breast cancer chemotherapy on taste function and food
hedonics across the treatment trajectory. The primary hypothesis
was that taste function and food hedonics would be adversely
affected by chemotherapy and that the greatest changes to taste
function and food hedonics would occur early in a chemotherapy
cycle. It was also hypothesised that changes in taste function and
food hedonics would be associated with alterations in dietary
intake and nutritional status. A secondary objective was to assess
the relationship between changes in taste function and toxicities.
Methods
Study Design
This was a prospective, multi-centre cohort study that recruited
patients planned for adjuvant chemotherapy for breast cancer at
three hospital-based oncology clinics in Melbourne, Australia from
April to December 2011. Potentially eligible patients were
identified via medical oncology clinics and breast cancer
multidisciplinary meetings.
Ethics statement
Institutional ethics approval was granted at Eastern Health and
Peter MacCallum Cancer Centre and written informed consent
was obtained from each patient before enrolment.
Participants
Patients aged 18 years or over scheduled to receive an
anthracycline and/or taxane containing chemotherapy regimen
for the adjuvant treatment of resected invasive breast cancer were
eligible to participate. Patients were required to be able to read
and converse in English. Exclusion criteria included chemotherapy
already initiated, concurrent radiotherapy, previous radiotherapy
to the head and neck region, or presence of cognitive impairment
that might impact study outcomes.
Variables
Outcome measures were number of tastants identified correctly,
food liking score, appetite rating, daily energy (kJ) and macronu-
trient (protein, fat and carbohydrate) intake, weight, body mass
index (BMI) and nutritional status (Figure 1). Demographic and
clinical data collected were obtained for age, years of education,
smoking status, BMI, concurrent medications, presence of
conditions implicated in taste function (liver or renal dysfunction,
sinusitis, diabetes) and treatment related toxicities (nausea, dry
mouth and oral mucositis).
Data sources and measurement
Figure 1 details study assessment time points and data collected.
Time points were selected in order to avoid days in the
chemotherapy cycle when patients may be taking corticosteroids.
Intra-cycle time points were chosen to assess effects early, middle
and late in a cycle. Stage of chemotherapy treatment was selected
based on a qualitative study with chemotherapy recipients who
reported symptoms being apparent by the third chemotherapy
cycle and resolving by 6–8 weeks after completion of chemother-
apy treatment [16].
Demographic and clinical data were obtained from the patients’
medical records and via direct questioning of the participant.
Clinical assessment of relevant chemotherapy toxicities was
performed at each study appointment in accordance with the
US Department of Health and Human Services Common
Terminology Criteria for Adverse Events (CTCAE) v.4.03, 2010.
Taste identification testing was performed in accordance with
the International Standards Organization (ISO), ISO 3972:2011-
Sensory Analysis-Methodology-Method of Investigating Sensitivity
of Taste as part of a taste identification task. Tastants and their
corresponding concentrations were: sucrose 300 mM, NaCl
200 mM, citric acid 5 mM, caffeine 10 mM, MSG 200 mM.
These solutions were prepared in the Deakin University sensory
laboratory from food grade chemicals and deionised water in the 7
day period prior to testing. At testing, five 2 ml solutions
corresponding to the five basic taste qualities (sweet, salty, sour,
bitter and umami) were each tasted in a single ‘sip and spit’
technique to determine the total number and individual tastants
identified correctly at each time point. The mouth was rinsed with
room temperature purified water three times before and after
sampling and expectorating each solution. Perceived taste quality
was identified by selecting one of seven choices. Correct responses
were sweet for sucrose, salty for NaCl, sour for citric acid, bitter for
caffeine, and savoury for MSG. Additional choices were none or
metallic. Taste identification score was assigned as 0–5 correct
choices.
Food liking was assessed using a 9-point hedonic scale [17] to
measure liking of a standard sweet (chocolate) and umami (soup)
food item from Like extremely (9) to Dislike extremely (1). Appetite
was rated on a 10-point scale from Best appetite (10) to Worst
appetite (1). Before all taste tests, participants were asked to refrain
from smoking, chewing gum, using toothpastes or other oral care
products, or eating or drinking anything other than water for a
minimum of one hour.
Dietary intake data for the preceding 24 hour period was
collected by a dietitian via telephone according to the United
States Department of Agriculture (USDA) automated multiple-
pass approach (AMPA) [18]. Dietary data were analysed using
FoodWorks 2007 (Xyris software, Queensland, Australia) and
daily nutrient intake was quantified as kilojoules and grams of
protein per kg of body weight and carbohydrate and fat as a
proportion of daily energy intake. Investigator assisted height and
self-reported weight were used to calculate BMI (kg/m2). The
Patient-Generated Subjective Global Assessment (PG-SGA) [19] is
a validated method of assessing and classifying nutritional status in
oncology populations and was used at baseline (T0) and 8 weeks
after completion of chemotherapy (T6) [20].
Sample size
Sample size requirements for this study were determined based
on estimates available for the hedonic scale and a difference
between baseline and final follow-up (where attrition would be
highest). In this case, sample size calculations were based on a
paired-samples t-test with an alpha level of 0.05, 80% power, a
Influence of Chemotherapy on Taste Function
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difference of 0.8 points in food liking and a standard deviation of
2.1 [17] (a standardised difference of 0.42). Given these
specifications, a total sample of 47 patients was required at final
follow-up. Assuming attrition of up to 10%, a minimum of 52
patients were needed at baseline.
Statistical analysis
Recruitment bias was assessed by comparing the age, treatment
centre and cancer stage of patients who consented to participate
and those who declined participation using t-tests and chi-squared
(or Fisher’s exact) tests as appropriate. Analysis of food liking and
appetite was carried out by fitting a linear mixed model to each
outcome separately; a reference cell model was used to generate
estimates of baseline means and differences between baseline and
follow-up assessments with 95% confidence intervals and tests of
significance. An unstructured covariance type was used to model
the covariance structure among repeated measures and all models
were estimated by maximum likelihood. McNemar’s test was used
to assess differences between proportions of participants correctly
identifying all five tastants at follow-up assessments compared with
baseline. Differences were also assessed for each tastant individ-
ually. An SPSS macro created by Garcia-Granero was used to
perform this test. [21] Confidence intervals generated by this
macro are based on methods developed by Newcombe [22].
Kendall’s Tau-b was used to examine associations of change scores
for number of tastants correctly identified and liking of sweet and
savoury test food items with change in BMI and PG-SGA score.
Frequency statistics were used to summarise treatment toxicities at
each time point and Kendall’s Tau-b was used to examine
associations of change scores for number of tastants correctly
identified with treatment toxicities at corresponding follow-up
assessments. Correlation coefficients were interpreted as follows:
0.1, small association; 0.3, medium association; and 0.5, large
association [23]. SPSS Windows Version 21 (Chicago, IL, USA)
was used for all analyses. No adjustments were made for
multiplicity.
Results
Fifty-two participants were enrolled in the study. Figure 2
summarises numbers of participants screened, approached and
recruited.
There were no differences between patients who consented to
participate and those who declined participation in terms of age,
treatment centre or stage of disease (all p.0.05). Compliance with
data collection was high at $96% for clinical variables, $94% for
demographic variables and $92% for all outcome measures.
Demographic, clinical and social characteristics of the sample are
shown in Table 1.
Change in taste function
Before adjuvant chemotherapy, 33% of participants correctly
identified all five tastants (Table 2). Taste function was reduced
with significantly fewer participants correctly identifying all five
tastants early cycle 3 (difference 218%, 95% CI 233, 23;
p=0.043) and early final cycle (difference 220%; 95% CI 235,
23; p=0.039) compared with baseline. Fewer participants
correctly identified all five tastants mid cycle 3 (difference 2
13%, 95% CI 228, 2; p=0.15) but this difference was not
significant and any effect had predominantly resolved by late cycle
3 (difference 24%, 95% CI 220, 12; p=0.79). There was no
difference between the proportions of participants who correctly
identified all five tastants pre-chemotherapy and 2 months post-
chemotherapy (difference 0%, 95% CI 215, 15; p=0.77).
At baseline and at all subsequent time points, sucrose as sweet
and caffeine as bitter were the most and least accurately identified
tastants respectively (Table 2). Further, compared with baseline,
there were no differences between the proportions of participants
who correctly identified either of these tastants at any follow-up
time point (all p.0.05). Conversely, there was a significant
reduction in the proportions of participants who correctly
identified MSG as savoury early cycle 3 (difference 216%, 95%
CI 229, 22; p=0.046) and NaCl as salty mid cycle 3 (difference
220%, 95% CI 235, 23; p=0.039) and early final cycle
Figure 1. Summary of outcome data collected at each study time point. aDay 12–13 of the third chemotherapy cycle if receiving 14 day
chemotherapy cycles. Cycle 3, Day 19–20 if receiving 21 day chemotherapy cycles.
doi:10.1371/journal.pone.0103512.g001
Influence of Chemotherapy on Taste Function
PLOS ONE | www.plosone.org 3 July 2014 | Volume 9 | Issue 7 | e103512
(difference 223%, 95% CI 239, 26; p=0.022). Compared with
baseline, fewer participants correctly identified citric acid as sour
at all subsequent time points (Table 2) but only the difference
between early final cycle and baseline reached significance
(difference 227%, 95% CI 241, 211; p=0.004).
Change in food hedonics
Food liking and appetite (Table 3) exhibited similar patterns of
differences as taste function indexed by total number of tastants
correctly identified. Compared with baseline, appetite was
significantly lower early cycle 3 (difference 2.1, 95% CI 22.9,
21.3; p,0.0005) and early final cycle (difference 2.1, 95% CI
23.0, 21.2; p,0.0005). Liking of sweet food was also significantly
lower early cycle 3 (difference 0.9, 95% CI 21.5, 20.4; p=0.002)
and early final cycle (difference 1.1, 95% CI 21.7, 20.5;
p=0.001), as well as mid cycle 3 (difference 0.8, 95% CI 21.4,
20.3; p=0.003), compared with before chemotherapy. Compared
with baseline, none of the differences in liking of savoury food at
subsequent time points were significant (all p.0.05).
Association between changes in taste function and
appetite and nutritional outcomes
Changes in taste function. There was a significant, medi-
um-sized association between a change in taste function and
kilojoule intake early cycle 3 (Tau-b = 0.31, p=0.008). Partici-
pants whose ability to correctly identify all five tastants deterio-
rated consumed fewer kilojoules per kilogram (Table 4).
Changes in appetite. There were significant, medium-sized
associations between reduced appetite early cycle 3 and reduced
kilojoule and protein intake (Tau-b = 0.34, p=0.002; and Tau-
b= 0.36, p=0.001, respectively) and decline in BMI early cycle 3
compared to baseline (Tau-b = 0.31, p=0.004). There was also a
significant, medium-sized association between changes in reduced
appetite and decline in BMI early final cycle compared to baseline
(Tau-b = 0.42, p,0.0005) (Table 4).
Association between changes in taste, chemotherapy
type and nutrition related toxicities
The majority of participants reported no symptoms of dry
mouth, oral mucositis or nausea at all time points assessed.
Nonetheless, there was a notable increase in the percentages of
patients reporting treatment-related toxicities early and mid cycle
3 and early final cycle. None of the associations between changes
in taste function at follow-up time points from before chemother-
apy and self-reported toxicities were significant (all p..05,
Table 5).
Discussion
The results of this study investigating women receiving adjuvant
chemotherapy support the hypothesis that taste function is
adversely affected by chemotherapy and that chemotherapy-
related effects are greatest early in a chemotherapy cycle. Further,
changes in taste function are cyclical and transient, as are changes
in food liking and appetite. The hypothesis that chemotherapy
related taste and hedonic changes are associated with alterations in
dietary intake and weight was also supported, although these
effects are experienced variably. Associations between change in
taste function and chemotherapy-related nausea, dry mouth and
mucositis, were typically small or trivial in size. Thus this study
contributes new knowledge in the area of chemotherapy-related
changes in taste function, food hedonics and nutritional outcomes
for women receiving adjuvant chemotherapy for breast cancer.
This is the first published study to have examined taste function
more than once within a single chemotherapy cycle in a sample
size greater than 10 participants and the first to assess perception
of all five basic taste qualities in an adult chemotherapy
population. Taste assessment in previous studies of chemotherapy
populations was conducted on the day of chemotherapy admin-
istration (late cycle) when patients report symptoms are at their
mildest. This flaw in methodology incorrectly suggested that taste
function may be unaffected by chemotherapy [24]. Data from the
Figure 2. CONSORT diagram reporting numbers of individuals at each stage of the study.
doi:10.1371/journal.pone.0103512.g002
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current study supports a recommendation that future research
incorporates early-mid cycle taste measurements in its design. It
has been shown previously that chemotherapy related taste
changes resolve some time between the end of treatment and 3
months after [25]. This study provides new evidence that for
breast cancer patients, taste problems experienced in the first 4–6
days after chemotherapy administration will likely resolve over the
course of a single chemotherapy cycle, repeat with each cycle and
resolve completely in as little as two months after chemotherapy
completion. These findings equip clinicians with accurate infor-
mation to provide breast cancer patients regarding expected
nature and duration of symptoms.
Given that patients undergoing chemotherapy commonly report
a reversal in preference for sweet or savoury foods and aversions to
items such as chocolate and coffee [26], the difference between
change in liking of the prototypical sweet food and prototypical
savoury food is noteworthy. It is not known whether a change in
taste function per se is responsible for the changes in liking of food
observed or whether this is driven more by changes in appetite or
as a result of other factors such as chemotherapy induced nausea.
It is postulated that the absence of a demonstrated decrease in
ability to identify sweet and bitter tastants may account for this
observation, suggesting these sweet and bitter taste qualities are
disproportionally (and aversively) perceptible over others. It has
been shown previously that hedonic scores for sucrose solutions
Table 1. Demographic, clinical and social characteristics of study participants and non-participants at baseline.
Characteristic Study sample Non-participants p valuea
Gender
Female n (%) 52 (100) 15 (100)
Age 0.35
Range 32–74 33–73
Mean 50.4 53.3
SD 9.7 11.6
Treatment Centre 0.78
Clinic A 25 9
Clinic B 9 1
Clinic C 18 5
Schooling years
Range 7–21
Mean 14.2
SD 3.2
BMI
IQR range 24.2–31.3
Median 26.9
Smoking status n (%)
Never smoked 24 (46)
Ex-smoker 24 (46)
Current smoker 4 (8)
Cancer stage n (%) 0.53
I 13 (25) 3 (20)
II 23 (44) 5 (33)
III 16 (31) 7 (47)
Scheduled chemotherapy treatment n (%)
bTaxane based regimens 24 (46)
cAnthracyline R Docetaxel 17 (33)
cAnthracyline R Paclitaxel 11 (21)
afor comparison of responders and non-responders;
bTaxane based regimens were: TC(4): Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks64 cycles: n=20 patients (38.5%); or 6 cycles: TC(6), n= 1
(1.9%); TCarbo: Docetaxel 75 mg/m2 plus carboplatin AUC 6 every 3 weeks66 cycles: n= 3 (5.8%);
cSequential anthracycline R taxane regimens were: AC(4)-T(4): Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 3 weeks64 cycles followed by
docetaxel 100 mg/m2 every 3 weeks64 cycles: n= 4 (7.7%); ddAC(4)-T(4): Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 every 2 weeks64 cycles followed
by paclitaxel 175 mg/m2 every 2 weeks64 cycles (with G-CSF during each of 8 cycles): n=5 (9.6%); AC(4)-T(12): Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/
m2 every 3 weeks64 cycles followed by paclitaxel 80 mg/m2 weekly612 cycles: n=2 (3.8%); ddAC(4)-T(12): Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2
every 2 weeks by 4 cycles (with G-CSF during each of 4 cycles) followed by paclitaxel 80 mg/m2 weekly612 cycles: n= 4 (7.7%); FEC(3)-D(3): 5-fluorouracil 500 mg/m2
plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 every 3 weeks followed by docetaxel 100 mg/m2 every 3 weeks63 cycles: n=13 (25.0%).
Notes. Cancer stage as per AJCC Cancer Staging Manual. Seventh edition. Numbers in parentheses are total chemotherapy cycles received for each type. dd = dose
dense (given over a 2-week cycle).
doi:10.1371/journal.pone.0103512.t001
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decrease at high concentrations in patients with poorest appetites
[27] suggesting that those with poorest appetites have greatest
aversion to intensely sweet items.
This study adds to limited existing evidence for the link between
taste and hedonic changes, dietary behaviour and nutritional
outcomes. Although a reduction in taste function was associated
with a lower kJ intake, appetite loss was more strongly related to
dietary inadequacy and weight loss than was change in taste
sensitivity. Reduced appetite had a medium-sized association with
reduced BMI and a small-sized association with worsening
nutritional status, however not all participants suffering taste or
appetite deficits lost weight. The relationship between taste and
food hedonics and alterations in dietary quality and nutritional
outcomes was specific to early breast cancer populations in this
study and should be tested in other clinical scenarios not least
because of bidirectional weight change and its variable clinical
implications.
Varying use of anti-nausea medications may be a confounding
factor in this study as nausea has previously been associated with
learned food aversions during chemotherapy treatment [28]. It is
postulated that degree of nausea control is likely to influence self-
rated appetite and food liking. Future studies should consider
incorporating a standardised anti-emetic regimen. Previous studies
of taste and food hedonics in chemotherapy populations suffered
from methodological issues of heterogeneity in cancer type, stage
and prescribed chemotherapy. This was not a factor in the current
study. However, time lapse between assessments did vary between
individuals within the sample due to differing number of
chemotherapy cycles administered, chemotherapy cycle length,
and treatment delays. The post-chemotherapy time point (T5)
represented a period of 5–8 months from the baseline assessment.
This variability has implications for nutritional outcome measures
as weight gain has previously been shown to vary with duration of
treatment in studies of women receiving adjuvant chemotherapy
for breast cancer [29].
Conclusions
Despite the stated limitations, this study characterised, for the
first time, changes in taste perception and food hedonics over
repeated chemotherapy cycles in women with early breast cancer
and provided evidence that taste per se, as opposed to other
elements of flavour is adversely affected at key points during
chemotherapy. Findings will inform the design of future studies
seeking to understand the mechanisms of changes in taste
perception during chemotherapy, and ultimately, the design of
interventions aimed at reducing the negative nutritional conse-
quences of chemotherapy treatment. Understanding more about
sensory risk factors for weight gain in breast cancer groups should
be prioritised in future clinical research, given the link between
obesity and poorer outcomes in this population.
Implementation of findings into practice
Patients do not systematically receive specific information
regarding the possible nature, timing of onset and duration of
taste problems by health professionals, nor are possible conse-
quences of changes or management strategies routinely discussed.
This research has generated new evidence to guide assessment and
predictors of chemotherapy induced sensory and hedonic changes.
Findings of the study will shape tailored patient information
provision in preparation for chemotherapy.
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